Arcus Biosciences (RCUS) Revenue & Revenue Breakdown
Arcus Biosciences Revenue Highlights
Latest Revenue (Y)
$117.00M
Latest Revenue (Q)
$39.00M
Main Segment (Y)
Other Collaboration Revenue
Arcus Biosciences Revenue by Period
Arcus Biosciences Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $117.00M | 4.46% |
| 2022-12-31 | $112.00M | -70.75% |
| 2021-12-31 | $382.88M | 393.93% |
| 2020-12-31 | $77.52M | 416.78% |
| 2019-12-31 | $15.00M | 79.58% |
| 2018-12-31 | $8.35M | 491.15% |
| 2017-12-31 | $1.41M | 100.00% |
| 2016-12-31 | - | - |
Arcus Biosciences generated $117.00M in revenue during NA 2023, up 4.46% compared to the previous quarter, and up 1400.69% compared to the same period a year ago.
Arcus Biosciences Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $39.00M | -73.10% |
| 2024-03-31 | $145.00M | 367.74% |
| 2023-12-31 | $31.00M | -3.13% |
| 2023-09-30 | $32.00M | 10.34% |
| 2023-06-30 | $29.00M | 16.00% |
| 2023-03-31 | $25.00M | 7146.38% |
| 2022-12-31 | $345.00K | -98.97% |
| 2022-09-30 | $33.58M | 25.49% |
| 2022-06-30 | $26.76M | 48.62% |
| 2022-03-31 | $18.00M | -94.92% |
| 2021-12-31 | $354.50M | 3646.95% |
| 2021-09-30 | $9.46M | - |
| 2021-06-30 | $9.46M | - |
| 2021-03-31 | $9.46M | -0.27% |
| 2020-12-31 | $9.49M | -85.30% |
| 2020-09-30 | $64.53M | 3587.43% |
| 2020-06-30 | $1.75M | - |
| 2020-03-31 | $1.75M | -82.05% |
| 2019-12-31 | $9.75M | 457.14% |
| 2019-09-30 | $1.75M | - |
| 2019-06-30 | $1.75M | - |
| 2019-03-31 | $1.75M | 12.04% |
| 2018-12-31 | $1.56M | -63.60% |
| 2018-09-30 | $4.29M | 243.28% |
| 2018-06-30 | $1.25M | - |
| 2018-03-31 | $1.25M | - |
| 2017-12-31 | $1.25M | 666.87% |
| 2017-09-30 | $163.00K | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | - |
Arcus Biosciences generated $39.00M in revenue during Q2 2024, up -73.10% compared to the previous quarter, and up 156.00% compared to the same period a year ago.
Arcus Biosciences Revenue Breakdown
Arcus Biosciences Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|
| Other Collaboration Revenue | $37.00M | $33.00M | - | - |
| License and Development Services Revenue | - | $74.00M | - | - |
| Gilead Access Rights | - | - | $30.91M | $15.42M |
| Gilead License to Domvanalimab | - | - | $328.84M | - |
| Taiho Access Rights | - | - | $7.00M | - |
| Taiho License to Domvanalimab | - | - | $15.00M | - |
| Development Services for all Gilead Programs | - | - | $1.14M | - |
| Gilead License To Zimberelimab | - | - | - | $55.10M |
| Taiho Collaboration Agreement | - | - | - | $7.00M |
Arcus Biosciences's latest annual revenue breakdown by segment (product or service), as of Dec 23: Other Collaboration Revenue (100.00%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other Collaboration Revenue | $10.00M | $9.00M | $10.00M | $10.00M | $8.00M | $8.05M | - | - | - | - | - | - | - | - | - |
| License and Development Services Revenue | $135.00M | $22.00M | $19.00M | $17.00M | $25.63M | - | - | - | - | - | - | - | - | - | - |
| Taiho Access Rights | - | - | - | - | - | - | $1.52M | $1.75M | $1.75M | - | - | - | - | - | - |
| Gilead Access Rights | - | - | - | - | - | - | $8.32M | $8.32M | $8.32M | $7.78M | $7.71M | $7.71M | $7.74M | $7.68M | - |
| License and Development Services for All Gilead Programs | - | - | - | - | - | - | $23.74M | $16.69M | $7.94M | - | - | - | - | - | - |
| License | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Collaboration | - | - | - | - | - | - | - | - | - | - | $7.71M | - | - | - | - |
| Taiho Collaboration Agreement | - | - | - | - | - | - | - | - | - | - | - | $1.75M | $1.75M | $1.75M | $1.75M |
| Gilead License To Zimberelimab | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $55.10M |
Arcus Biosciences's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: License and Development Services Revenue (93.10%), and Other Collaboration Revenue (6.90%).
Arcus Biosciences Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| PTCT | PTC Therapeutics | $937.82M | $186.70M |
| APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
| BPMC | Blueprint Medicines | $249.38M | $138.16M |
| RCUS | Arcus Biosciences | $117.00M | $39.00M |
| KRYS | Krystal Biotech | $50.70M | $70.28M |
| VECT | VectivBio | $27.34M | $676.00K |
| RLAY | Relay Therapeutics | $25.55M | - |
| TCRX | TScan Therapeutics | $21.05M | - |
| ITOS | iTeos Therapeutics | $12.60M | - |
| CGEM | Cullinan Oncology | - | - |
| GPCR | Structure Therapeutics | - | - |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| AVRO | AVROBIO | - | - |
| CNSP | CNS Pharmaceuticals | - | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| ANNX | Annexon | - | - |
| MDGL | Madrigal Pharmaceuticals | - | - |
| IMMX | Immix Biopharma | - | - |
| HEPA | Hepion Pharmaceuticals | - | - |
RCUS Revenue FAQ
What is Arcus Biosciences’s yearly revenue?
Arcus Biosciences's yearly revenue for 2023 was $117M, representing an increase of 4.46% compared to 2022. The company's yearly revenue for 2022 was $112M, representing a decrease of -70.75% compared to 2021. RCUS's yearly revenue for 2021 was $382.88M, representing an increase of 393.93% compared to 2020.
What is Arcus Biosciences’s quarterly revenue?
Arcus Biosciences's quarterly revenue for Q2 2024 was $39M, a -73.10% decrease from the previous quarter (Q1 2024), and a 34.48% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $145M, a 367.74% increase from the previous quarter (Q4 2023), and a 480.00% increase year-over-year (Q1 2023). RCUS's quarterly revenue for Q4 2023 was $31M, a -3.12% decrease from the previous quarter (Q3 2023), and a 8885.51% increase year-over-year (Q4 2022).
What is Arcus Biosciences’s revenue growth rate?
Arcus Biosciences's revenue growth rate for the last 3 years (2021-2023) was -69.44%, and for the last 5 years (2019-2023) was 680.00%.
What are Arcus Biosciences’s revenue streams?
Arcus Biosciences's revenue streams in c 23 are Other Collaboration Revenue
What is Arcus Biosciences’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Arcus Biosciences was Other Collaboration Revenue. This segment made a revenue of $37M, representing 100.00% of the company's total revenue.